About Zosano Pharma
Redefining Transdermal Delivery
Zosano Pharma is an emerging development company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company’s proprietary transdermal delivery system.
The Company’s goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action.
Zosano Pharma’s investigational migraine treatment Qtrypta™ (M207)(zolmitriptan intracutaneous microneedle system)* is a novel formulation of zolmitriptan, a drug used orally and nasally to effectively and safely treat acute migraine, administered via the Company’s proprietary transdermal delivery system. Qtrypta (M207) is being investigated as a potential treatment to provide rapid relief of migraine symptoms, at any time in the migraine cycle, in a discreet and simple manner.
Zosano Pharma has developed its proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications. The Company’s transdermal delivery system offers rapid and consistent drug delivery, improved ease of use and room-temperature stability, all of which are benefits that the Company believes are often unavailable using oral formulations or injections and offer important therapeutic and practical advantages that address unmet needs with large patient populations.
By focusing the Company’s development efforts on the delivery of established molecules with known safety and efficacy, Zosano Pharma anticipates a reduction in clinical and regulatory risk and development costs and acceleration in time to commercialization.
* Qtrypta (zolmitriptan intracutaneous microneedle system) is the proposed tradename that has been conditionally approved by FDA. Zosano will seek approval of the tradename when an NDA is filed for the product.